Why the study?
Does intracoronary verapamil injection reduce the incidence of coronary no-reflow in patients with acute coronary syndrome undergoing PCI?
Does intracoronary verapamil injection reduce the incidence of coronary no-reflow in patients with acute coronary syndrome undergoing PCI?
Intracoronary verapamil administration during PCI for ACS significantly reduces the incidence of angiographic no-reflow and improves short-term clinical outcomes.
Answers are grounded in this paper and cite their sources.
Supports intracoronary verapamil in ACS PCI to reduce no-reflow; confirms short-term MACE reduction in pooled analyses.
BACKGROUND: To evaluate the clinical efficacy and safety of intracoronary verapamil injection in the prevention and treatment of coronary no-reflow after percutaneous coronary intervention (PCI). HYPOTHESIS: Intracoronary verapamil injection may be beneficial in preventing no-reflow/slow-flow after PCI. METHODS: We searched PubMed, Embase, and the Cochrane Central Register of Controlled Trials database. Randomized trials comparing the efficacy and safety of intracoronary verapamil infusion vs control in patients with acute coronary syndrome (ACS) were included. Meta-analysis was performed by RevMan 5.0 software (Cochrane Collaboration, Copenhagen, Denmark) . RESULTS: Seven trials involving 539 patients were included in the analysis. Verapamil treatment was significantly more effective in decreasing the incidence of no-reflow (risk ratio [RR]: 0.33; 95% confidence interval [CI]: 0.23 to 0.50) as well as reducing the corrected thrombolysis in myocardial infarction (TIMI) frame count (CTFC) (weighted mean difference: -11.62; 95% CI: -16.04 to -7.21) and improving the TIMI myocardial perfusion grade (TMPG) (RR: 0.43; 95% CI: 0.29 to 0.64). Verapamil also reduced the 30-day wall motion index (WMI) compared to the control. Moreover, the procedure reduced the incidence of major adverse cardiac events (MACEs) in ACS patients during hospitalization (RR: 0.37; 95% CI: 0.17 to 0.80) and 2 months after PCI (RR: 0.56; 95% CI: 0.33 to 0.95). However, administration of verapamil did not provide an additional improvement of left ventricular ejection fraction regardless of the time that had passed post-PCI. CONCLUSIONS: Intracoronary verapamil injection is beneficial in preventing no-reflow/slow-flow, reducing CTFC, improving TMPG, and lowering WMI. It is also likely to reduce the 2-month MACEs in ACS patients post-PCI.
No takes yet. Share an insight, caveat, or question.
Su et al. (2013) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: